Now Is The Time To Build A Position In Vir Biotechnology Inc (NASDAQ:VIR)

Vir Biotechnology Inc (NASDAQ:VIR) has a beta value of 1.09 and has seen 1.59 million shares traded in the last trading session. The company, currently valued at $1.01B, closed the last trade at $7.34 per share which meant it lost -$0.03 on the day or -0.41% during that session. The VIR stock price is -96.87% off its 52-week high price of $14.45 and 10.63% above the 52-week low of $6.56.

The consensus among analysts is that Vir Biotechnology Inc (VIR) is Buy stock at the moment, with a recommendation rating of 1.56. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 10 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.84.

Vir Biotechnology Inc (NASDAQ:VIR) trade information

Sporting -0.41% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the VIR stock price touched $7.34 or saw a rise of 13.75%. Year-to-date, Vir Biotechnology Inc shares have moved 0.00%, while the 5-day performance has seen it change -10.49%. Over the past 30 days, the shares of Vir Biotechnology Inc (NASDAQ:VIR) have changed -25.41%.

Wall Street analysts have a consensus price target for the stock at $20, which means that the shares’ value could jump 63.3% from current levels. The projected low price target is $20.0 while the price target rests at a high of $20.0. In that case, then, we find that the current price level is -172.48% off the targeted high while a plunge would see the stock gain -172.48% from current levels.

Vir Biotechnology Inc (VIR) estimates and forecasts

The company’s shares have lost -5.41% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -62.98%.

6 analysts offering their estimates for the company have set an average revenue estimate of 8.59M for the current quarter. 6 have an estimated revenue figure of 6.79M for the next ending quarter. Year-ago sales stood 56.38M and 3.08M respectively for this quarter and the next, and analysts expect sales will shrink by -84.76% for the current quarter and -62.98% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -18.74% over the past 5 years. Earnings growth for 2025 is a modest 12.21% while over the next 5 years, the company’s earnings are expected to increase by 10.12%.

VIR Dividends

Vir Biotechnology Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Vir Biotechnology Inc (NASDAQ:VIR)’s Major holders

The top two institutional holders are SB INVESTMENT ADVISERS (UK) LTD with over 16.68 million shares worth more than $148.49 million. As of 2024-06-30, SB INVESTMENT ADVISERS (UK) LTD held 12.2466% of shares outstanding.

The other major institutional holder is BLACKROCK INC., with the holding of over 16.43 million shares as of 2024-06-30. The firm’s total holdings are worth over $146.26 million and represent 12.1482% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 4.33% shares in the company for having 5.94 shares of worth $43.62 million while later fund manager owns 3.44 shares of worth $25.25 million as of Dec 31, 2024 , which makes it owner of about 2.51% of company’s outstanding stock.